Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||renal cell carcinoma||no benefit||AGS-003 + Sunitinib||Phase II||Actionable||In a Phase II clinical trial, treatment with the combination of AGS-003 and Sutent (sunitinib) resulted in clinical benefit in 62% (13/21) of patients with advanced renal cell carcinoma, with 9 partial responses and 4 patients achieving stable disease, a median overall survival of 30.2 months, and median progression-free survival of 11.2 months (PMID: 25901286).||25901286|
|Unknown unknown||renal cell carcinoma||no benefit||AGS-003 + Sunitinib||Phase III||Actionable||In a Phase III trial (ADAPT), the combination of AGS-003 (Rocapuldencel-T) and Sutent (sunitinib) did not demonstrate improved efficacy compared to Sutent alone in metastatic renal cell carcinoma patients, resulting in median overall survival of 27.7 v 32.4 months, progression-free survival of 6.0 v 7.83 months, and objective response rate of 42.7% (131/307, 9 complete, 122 partial) v 39.4% (61/155, 3 complete, 58 partial) in the combination or monotherapy groups, respectively (PMID: 32034074; NCT01582672).||32034074|
|PubMed Id||Reference Title||Details|
|(25901286)||Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results.||Full reference...|
|(32034074)||Results of the ADAPT Phase 3 Study of Rocapuldencel-T in Combination with Sunitinib as First-Line Therapy in Patients with Metastatic Renal Cell Carcinoma.||Full reference...|